This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY)

This study has been completed.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: September 1, 2009
Last updated: November 25, 2016
Last verified: November 2016
This is a randomized, double-blind, placebo controlled, four-arm, dose-ranging study. The purpose is to evaluate the relationship between the dose of lebrikizumab and the response in terms of the efficacy, safety, and tolerability in patients with asthma who are not on inhaled steroids.

Condition Intervention Phase
Asthma Drug: lebrikizumab (MILR1444A) Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY)

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Change in forced expiratory volume in 1 second (FEV1) [ Time Frame: Baseline to Week 12 ]

Secondary Outcome Measures:
  • Change in pre-bronchodilator FEV1 [ Time Frame: Baseline to Week 24 ]
  • Change in quality of life and symptom scores [ Time Frame: Baseline to Week 12 ]
  • Change in peak flow [ Time Frame: Baseline to Week 1 ]
  • Rate of asthma exacerbations [ Time Frame: During the 24-week treatment period ]
  • Change in rescue medication use [ Time Frame: From baseline to Week 1 ]
  • Frequency and severity of adverse events [ Time Frame: From the first study-specific procedure through the last observation visit ]
  • Incidence of human anti-therapeutic antibodies (ATA) [ Time Frame: Baseline to Week 32 ]

Enrollment: 210
Study Start Date: November 2009
Study Completion Date: February 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: lebrikizumab (MILR1444A)
Subcutaneous repeating dose
Experimental: B Drug: lebrikizumab (MILR1444A)
Subcutaneous repeating dose
Experimental: C Drug: lebrikizumab (MILR1444A)
Subcutaneous repeating dose
Placebo Comparator: D Drug: placebo
Subcutaneous repeating dose


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body weight ≥ 50 kg and ≤ 150 kg at Visit 1
  • Chest radiograph within 12 months of Visit 1 without evidence of a clinically significant abnormality
  • Stable asthma

Exclusion Criteria:

  • Asthma exacerbation during screening
  • Known malignancy
  • Known immunodeficiency
  • Pre-existing lung disease other than asthma
  • Uncontrolled clinically significant medical disease
  • Current smoker
  • History of substance abuse that may impair or risk the patient's full participation in the study, in the judgment of the investigator
  • Prior allergic reaction to a monoclonal antibody
  • Patients (men and women) of reproductive potential who are not willing to use contraception
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00971035

Sponsors and Collaborators
Genentech, Inc.
Study Director: Michelle Freemer, M.D. Genentech, Inc.
  More Information

Responsible Party: Genentech, Inc. Identifier: NCT00971035     History of Changes
Other Study ID Numbers: ILR4660g
Study First Received: September 1, 2009
Last Updated: November 25, 2016

Keywords provided by Genentech, Inc.:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on July 26, 2017